Overview of Reflexan

Quick Facts

Property	Description
Active ingredient	Cyclobenzaprine Hydrochloride
Form	Tablet, Capsule (Oral)
Pharmacological class	Skeletal Muscle Relaxant
Common use	Relief of acute muscle spasm
Origin	Synthetic, Dibenzocycloheptadiene derivative

The Identity of Reflexan: A Synthetic Muscle Relaxant

Reflexan is a prescription-only medication whose active component is Cyclobenzaprine Hydrochloride. It is formally classified as a Skeletal Muscle Relaxant, a drug category used to manage conditions involving muscle tightness and pain.

The substance itself is synthetic, chemically derived as a Dibenzocycloheptadiene derivative, giving it a structure related to tricyclic compounds. Cyclobenzaprine Hydrochloride is supplied as a single-ingredient product in oral forms, specifically a conventional tablet and an extended-release formulation capsule. This medicine is structurally distinct from other muscle relaxants, possessing unique chemical properties. This distinction means the drug operates via a specific central pathway to achieve muscle relaxation.

Pharmacological Class and General Purpose

Reflexan functions as a Centrally Acting Muscle Relaxant, meaning its therapeutic effect targets the Central Nervous System (CNS), particularly the pathways located in the brainstem and spinal cord. Its primary mechanism involves polysynaptic reflex inhibition, which reduces the hyperactive nerve signals that cause sustained, involuntary muscle contraction.

Cyclobenzaprine is indicated for use as adjunctive therapy—meaning it works alongside rest and physical therapy—to relieve acute muscle spasm associated with musculoskeletal conditions. The medicine's general purpose is to break the localized spasm-pain cycle, helping to restore comfort and mobility during the initial recovery phase.

What side effects are possible with Reflexan?

Possible Side Effects and Safety Information

The safety profile of Reflexan (Cyclobenzaprine Hydrochloride) is documented based on frequency and system-organ class, as reported in official regulatory documents.

Frequency-Classified Adverse Reactions

The most commonly reported adverse reactions in clinical studies include Somnolence (Drowsiness), Dry Mouth (Xerostomia), and Dizziness, which are classified as Most Common events. Other Common reactions (incidence 1%-3%) include headache, fatigue, confusion, and constipation. Less common reactions reported in post-marketing surveillance include syncope, tachycardia, and hallucinations.

Serious Adverse Reactions and Constraints

Official labeling warns of the potential for Serotonin Syndrome when used alongside other serotonergic medications, requiring careful observation, especially during treatment initiation or dosage increases. Due to its structural similarity, the drug shares the toxic potential of related compounds, including serious cardiovascular events such as myocardial infarction and arrhythmias.

Safety restrictions prohibit its use in patients with hyperthyroidism and those in the acute recovery phase of a myocardial infarction, as well as patients taking Monoamine Oxidase (MAO) inhibitors.

Population-Specific Safety Notes

The regulatory profile places specific limits on use for certain populations. The extended-release form is not recommended for use in older adults, where the frequency and severity of adverse events are documented to be increased. Use is also not recommended in patients with moderate to severe hepatic impairment (immediate-release) or any degree of hepatic impairment (extended-release), due to increased plasma concentration.

Overdose and Emergency Response

Overdose and when to seek help

In the event of a suspected overdose of Reflexan (Cyclobenzaprine Hydrochloride), immediate emergency medical attention must be sought without delay. Contact emergency services or a poison control center if the individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. Hospital monitoring is required in all suspected cases, as severe signs of toxicity may develop rapidly.

Documented manifestations commonly include drowsiness and rapid heart rate (tachycardia). However, regulatory labeling also documents severe, potentially life-threatening outcomes, such as cardiac dysrhythmias, severe hypotension, seizures, and coma. The development of Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS) is also documented in the official prescribing information.

Management protocols outlined in official sources emphasize symptomatic and supportive treatment. Treatment involves obtaining an ECG, initiating cardiac monitoring, and providing supportive care for cardiovascular and central nervous system effects. Procedures like gastrointestinal decontamination, which may include gastric lavage followed by activated charcoal, are officially described. Emesis (induced vomiting) is contraindicated. No specific antidote is known.

Population-specific considerations note an increased risk of toxicity in elderly patients and those with hepatic impairment due to significantly higher plasma concentrations and prolonged drug half-life. Use of the extended-release formulation is officially not recommended in these vulnerable populations.

Therapeutic Uses of Reflexan

Quick Facts: Reflexan Uses

Relief of Muscle Spasm: Indicated for use in conjunction with rest and physical therapy.
Acute Musculoskeletal Conditions: Indicated for the short-term management of muscle spasms associated with acute, painful conditions.
Aims to Reduce Discomfort: Intended to help ease pain and related stiffness in the muscles.

Reflexan is a prescription medication indicated for the temporary management of skeletal muscle spasms. This therapy is specifically utilized as an adjunct to physical therapy and rest for relieving muscle spasms linked to acute, painful musculoskeletal conditions. The intended benefit is to support the reduction of associated pain and discomfort, and to facilitate an improved range of motion in the affected area.

The use of this medication is typically reserved for short-term periods, generally not exceeding two to three weeks, as efficacy for prolonged treatment is not established. It is important to note that Reflexan is not a treatment for spasticity resulting from cerebral or spinal cord disease. Patients should always consult with a healthcare professional to determine if this treatment option is appropriate for their individual clinical needs and to understand the short-term nature of the therapy.

Regulatory References

NIH MedlinePlus guidance on Cyclobenzaprine

Eligibility and Restrictions for Use

Eligibility Scope

The use of Reflexan (Cyclobenzaprine) is limited to adults and adolescents 15 years of age and older. Use is not recommended in older adults 65 years and over due to pharmacokinetic differences that increase drug exposure and potential risk. Safety and effectiveness are not established in the pediatric population younger than 15.

Contraindications (Who Must Not Use)

Reflexan is strictly contraindicated in several patient populations. It must not be used by individuals with known hypersensitivity to the drug or those who are taking Monoamine Oxidase (MAO) inhibitors (or within 14 days of stopping one). Absolute exclusions also apply to patients with specific cardiovascular conditions, including the acute recovery phase of a heart attack, arrhythmias, heart block, or congestive heart failure, as well as those with hyperthyroidism.

Eligibility Restrictions

The official labeling also outlines restrictions for organ function. Use is not recommended for patients with moderate or severe hepatic (liver) impairment, and caution is required for those with mild impairment. Conditional use is necessary for individuals with a history of angle-closure glaucoma or urinary retention. For pregnancy, use is permitted only if clearly needed, while lactation requires a careful assessment of risk versus benefit.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Reflexan (Cyclobenzaprine Hydrochloride) has several documented interaction patterns primarily concerning pharmacodynamic effects and pharmacokinetic modifications, as detailed in official regulatory prescribing information.

Pharmacodynamic Interactions and Restrictions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated. This prohibition includes concomitant use or administration within 14 days of discontinuing an MAOI, due to the documented risk of hyperpyretic crisis, seizures, and death.

Additive effects are seen with Central Nervous System (CNS) depressants, including alcohol, barbiturates, and opioid medications, resulting in enhanced CNS depression. The use of Reflexan with other serotonergic drugs (e.g., SSRIs, SNRIs) carries a documented risk for developing Serotonin Syndrome.

Pharmacokinetic and Population Considerations

Reflexan is metabolized by Cytochrome P450 enzymes, primarily CYP3A4 and CYP1A2, which forms the basis for potential metabolic interactions. For the extended-release capsule, administration with food increases both the peak plasma concentration ( C max) by approximately 35% and overall systemic exposure ( AUC) by 20%.

In patients with mild hepatic impairment, studies show that the AUC and C max are approximately double compared to healthy subjects. Consequently, regulatory guidance advises caution in mild impairment and states that use is not recommended in moderate or severe hepatic impairment. Extended-release formulations are also generally not recommended for use in elderly patients.

Mechanism of Action

GABAB Receptor Modulation

Reflexan is a novel small molecule that acts as a selective positive allosteric modulator (PAM) of the GABA B receptor, targeting the GABA B(1) and GABA B(2) heterodimer. This interaction increases the binding affinity of endogenous GABA, which enhances receptor activation. By promoting GABA B signaling in the dorsal horn of the spinal cord, Reflexan reduces the release of glutamate and substance P, which are key pronociceptive neurotransmitters. This targeted modulation subsequently enhances local inhibitory neurotransmission.

T-Type Calcium Channel Inhibition and Dual Action

Furthermore, Reflexan also demonstrates inhibition of the Ca v3.2 T-type calcium channel, which regulates neuronal firing in sensory neurons. The dual mechanism involves modulation of both GABA B receptor activity and Ca v3.2 T-type calcium channel conductance.

Dosage and Administration Information

How to Use Reflexan

Reflexan (Cyclobenzaprine Hydrochloride) is administered orally in two primary forms: an immediate-release (IR) tablet and an extended-release (ER) capsule. The use of this medicine is strictly limited to short periods, generally up to two or three weeks, as its effectiveness beyond this duration has not been established.

Dosing and Frequency

Dosing Form	Standard Adult Regimen	Frequency	Maximum Daily Dose
IR Tablet (5 mg, 7.5 mg, 10 mg)	Start with 5 mg	Three times a day (TID)	60 mg in divided doses
ER Capsule (15 mg, 30 mg)	Start with 15 mg	Once daily	30 mg

The IR dose may be increased to 10 mg TID based on patient response. The ER capsule should be taken at approximately the same time each day.

Administration Requirements

Both the tablet and the capsule can be taken with or without food. For the ER capsule, the contents may be swallowed whole, or the contents may be sprinkled onto a tablespoon of applesauce and swallowed immediately without chewing. The mixture must not be saved for later use.

Population-Specific Use

Dosage adjustments are specified for certain patient groups. In older adults and patients with mild hepatic impairment, treatment with the IR tablet should begin at the lower 5 mg dose and be titrated slowly. The ER capsule is generally not recommended for these groups due to altered metabolism. For pediatric use, the medicine is indicated for individuals 15 years of age and older at the adult immediate-release dosing.

Recent Clinical Evidence

Research evidence / Overview of studies for Reflexan

Evidence for Use in Acute Muscle Spasm

Research has explored Reflexan's use in clinical trials as an adjunct to rest and physical therapy, primarily relying on Randomized Controlled Trials (RCTs) and subsequent meta-analyses. These studies focused on patients dealing with acute muscle spasm linked to painful musculoskeletal conditions such as low back or neck pain. The body of evidence confirms that trials were designed to examine outcomes related to the assessment of spasm and associated pain but do not include studies related to muscle spasticity resulting from conditions of the brain or spinal cord.

Study Outcomes and Measures Examined

Researchers examined various outcomes reflecting daily functioning, including the Patient-Rated Global Impression of Change and scores related to patient-reported experience. Studies also monitored physical metrics such as muscle spasm intensity and limited motion. In comparing Reflexan to an inactive pill (placebo), findings indicated differences between the observed group and the placebo group. However, meta-analyses often describe the findings related to specific outcomes, such as pain and functional measures, as modest across the pooled study populations.

Study Duration and Long-Term Follow-up

The research is characterized by short-term follow-up durations, typically ranging from 7 to 18 days. Research highlights changes measured during the initial study period, often suggesting that the measured differences in symptoms were most apparent within the first few days of the observed responses. A key point in the broader evidence landscape is that long-term effects are not fully established, with limited information available regarding the effectiveness of Reflexan when used beyond two to three weeks.

Evidence in Different Patient Populations and Research Gaps

The primary clinical research was conducted in the general adult population. Findings related to certain groups remain insufficient; for example, regulatory evidence for certain extended-release formulations indicates these are not established for use in the elderly population, and data are not available to establish safety or effectiveness in children. Key research gaps include the lack of comparative evidence versus other therapies, while overall findings indicate that differences in reported study observations were noted compared to placebo in the observed study populations.

Key Studies & References Cyclobenzaprine (MedlinePlus Drug Information)

Frequently Asked Questions (FAQ)

Common questions about Reflexan (FAQ)

Q: How quickly should I notice the effects of Reflexan?

Studies and official product information indicate that the effects of the medicine typically begin to be noticeable around one hour after it is taken. The total duration of the medicine's effect varies depending on the formulation.

Q: Is it normal to feel a bit nauseous when starting Reflexan?

Official safety information from clinical studies notes that nausea is a reported side effect of the medicine. It is classified among the range of adverse reactions that users may experience, particularly when first starting the treatment.

Q: How long does one dose of Reflexan last in the body?

According to the official clinical pharmacology data, the medicine has a long effective half-life, meaning it stays in the body for an extended period, described as approximately 18 hours. However, the therapeutic effect on muscle spasm relief is often shorter than the time the drug remains detectable in the body.

Q: Do I need to avoid certain foods while taking Reflexan?

For the extended-release capsule, official administration instructions specify that the contents may only be mixed and swallowed with applesauce if not taken whole. This is because regulatory studies have not tested the effects of mixing the contents with other specific foods.

Q: Is there a generic version of Reflexan available?

Yes, the active ingredient in Reflexan, Cyclobenzaprine Hydrochloride, is widely available in generic form. Generic versions contain the same active ingredient, strength, and dosage form as the brand name product.

Q: Are there any known long-term side effects of taking Reflexan?

Studies and official documents primarily concern short periods of treatment, generally limited to two to three weeks. Because of this, official regulatory research states that the long-term effects and safety profile of the medicine beyond this short duration are not fully established.

Q: Is Reflexan safe for people with high blood pressure?

The medicine is strictly forbidden for use by patients with certain severe heart conditions, such as heart block or heart failure. Furthermore, official adverse reaction reports list changes in blood pressure, including episodes of hypertension (high blood pressure), as a reported side effect.

Q: Can taking Reflexan affect my ability to drive or operate machinery?

Official patient information carries a warning that the medicine may cause drowsiness and dizziness. Due to the potential for these effects to impair mental and physical abilities, official warnings advise against operating hazardous machinery, including driving, while using the medication.

Q: Is it possible to become dependent on Reflexan?

No, the medicine is not classified as a controlled substance by the DEA, and it is not known to have the physical dependence or abuse potential of some other substances. However, abrupt discontinuation of the medicine has been associated with reports of withdrawal symptoms, such as headache and nausea.

Q: Does Reflexan have any known interactions with herbal products?

The official label contains warnings about potential interactions with other serotonergic drugs, which increase serotonin activity. Some herbal supplements, notably St. John's Wort, are listed in this category and carry a documented risk of causing Serotonin Syndrome if taken with Reflexan.

Q: Is Reflexan a controlled substance?

No, the medicine's active ingredient, Cyclobenzaprine, is not scheduled as a controlled substance under the U.S. Controlled Substances Act (CSA) by the Drug Enforcement Administration (DEA).

Q: Why does the official leaflet list so many possible side effects?

Regulatory bodies require official documents to include an extensive list of all adverse events reported during clinical studies, even if the medicine was not confirmed as the cause. This process ensures comprehensive safety monitoring and is the reason the official leaflet may contain a long list of possible side effects.

Q: Can Reflexan affect the results of lab tests?

The medicine is chemically similar to tricyclic antidepressants (TCAs). Because of this structural relationship, official documents note that it may potentially cause a false positive result for TCAs on some common laboratory drug screening tests.

Q: Are there any known genetic factors that affect how Reflexan works?

The medicine is processed (metabolized) by specific liver enzymes, including CYP3A4 and CYP1A2. Since these enzymes are often affected by natural genetic variations in people, these factors can potentially influence the levels of the drug in the body.

Q: Is Reflexan a new medication?

The active ingredient in Reflexan (Cyclobenzaprine) is not a new medicine. Official drug approval records indicate that its initial approval for use in the U.S. dates back to 1977.

Q: What official bodies have approved Reflexan?

The medicine has been approved for use by major health regulatory bodies. These include the U.S. Food and Drug Administration (FDA) and similar health agencies in other international jurisdictions.

Q: Is it true that Reflexan needs to be stopped slowly, not suddenly?

Official reports mention that symptoms like headache and nausea have been reported after the medicine was stopped abruptly. For this reason, official guidance indicates that the medicine may need to be stopped gradually, following a specific plan determined by a healthcare provider.

Q: Why are there different brand names for the same medicine as Reflexan?

The active ingredient, Cyclobenzaprine Hydrochloride, is marketed under the original brand name (Reflexan) as well as numerous generic brand names. This is standard practice following regulatory approval for generic competition.

Q: What happens if Reflexan is taken past its expiration date?

Expiration dates are set based on stability tests to guarantee the medicine's full potency and safety. Official regulatory principles state that taking the medicine past its expiration date means there is no official guarantee of its quality, stability, or effectiveness.

How should Reflexan be stored and disposed of?

Official Storage and Disposal Profile

The storage and disposal requirements for Reflexan (Cyclobenzaprine HCl) are strictly defined in regulatory documents to ensure product efficacy and public safety.

Scope Item	Official Regulatory Requirement
Storage Temperature	Store at 20 C to 25 C (68 F to 77 F), with permitted excursions between 15 C and 30 C [1.2, 1.7].
Environmental Protection	Protect from excess heat and moisture and direct light. Keep the medicine from freezing [3.4, 3.6].
Packaging Rules	The medication must be kept in the container it came in, tightly closed, and dispensed in a tight, light-resistant container [1.2, 3.6].
Child Safety	Keep out of the sight and reach of children and pets. Store the product locked up [1.1, 3.6].
Disposal	Disposal should use a drug take-back program. If one is unavailable, mix the unused medicine with an undesirable substance (e.g., dirt, cat litter) and place it in a sealed bag for the household trash [3.1, 3.7].

This structure reflects the mandated conditions for keeping the product stable and outlines the official pathway for discarding unused medicine, which includes the necessary step of scratching out personal information on the packaging.

Reflexan